How to Solve The Advanced Therapies Skills Shortage

Training talent from other highly regulated industries, apprenticeships and targeting primary schools are key to addressing the skills shortage in the advanced therapies space.

Arrow
Apprenticeships and recruiting from other industries could address skills shortages in the advanced therapies sector • Source: Alamy

The advanced therapies industry in the UK and elsewhere is facing a shortage of skilled employees when it comes to the areas of manufacturing, quality and R&D, however there are some solutions, heard delegates at the recent Advanced Therapies 2022 congress in London.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cell Therapies

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

Gilead Pipeline Progress Offsets Oncology Sales Slowdown

 

Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

 

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.

More from Advanced Therapies

Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib Results

 

The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.

Novartis $23bn US Investment Is Music To Trump’s Ears

 
• By 

The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By 

Adstiladrin sales hit €70m in first full year on the market